GlassScriptPhysician profile
Sarah Taylor
NPI 1033372123
$2,085.11
in general payments reported to CMS, 2019-2025
31 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.28 · 2021: $26.33 · 2022: $483 · 2023: $658 · 2024: $392 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $298.29 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $286.15 | 2022-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $275.33 | 2022-2025 | |
| Lilly USA, LLC | $137.06 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $113.13 | 2022 | |
| Astellas Pharma US INC | $106.82 | 2022-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $86.29 | 2021-2025 | Wegovy, Ozempic, Saxenda |
| Glaxosmithkline, LLC. | $82.39 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Axsome Therapeutics, INC. | $79.68 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $59.20 | 2022-2024 | Farxiga |
| Amgen INC. | $58.36 | 2022-2025 | Evenity, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $53.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.72 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $47.59 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $41.84 | 2019-2025 | Vaxelis, Gardasil 9, Capvaxive |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $35.01 | 2022-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $28.12 | 2025 | |
| Alexion Pharmaceuticals, INC. | $23.62 | 2024 | Strensiq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.13 | 2024 | Caplyta |
| Alkermes, INC. | $20.67 | 2023 | Aristada, Lybalvi |
| Optinose US, INC. | $19.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.77 | 2024 | Gattex |
| Bayer Healthcare Pharmaceuticals INC. | $18.51 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.00 | 2024 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $16.64 | 2023 | Krystexxa |
| Medtronic, INC. | $16.60 | 2023 | Minimed 770g |
| Dexcom, INC. | $16.60 | 2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.32 | 2024 | Xifaxan |
| Evoke Pharma, INC. | $16.16 | 2023 | Gimoti |
| Ultragenyx Pharmaceutical INC. | $13.53 | 2021 | |
| Ethicon US, LLC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.